The pandemic continues to cause unprecedented disruption across industries worldwide.
Get detailed insights regarding the impact of COVID-19 on the market.
The global HIV drugs market reached a value of US$ 29.2 Billion in 2021. Looking forward, IMARC Group expects the market to reach US$ 38.9 Billion by 2027, exhibiting a CAGR of 3.7% during 2022-2027. Keeping in mind the uncertainties of COVID-19, we are continuously tracking and evaluating the direct as well as the indirect influence of the pandemic. These insights are included in the report as a major market contributor.
Human Immunodeficiency Virus (HIV) is a chronic and life-threatening disease which can be transferred from one person to another through blood-to-blood and sexual contact. It is a virus which attacks immune cells known as CD-4 cells, making body susceptible to infections and other diseases. Over the years, the rising prevalence of HIV disease worldwide has positively influenced the demand for HIV drugs. HIV drugs help in preventing the multiplication of HIV, thereby reducing the risk of its transmission.
One of the primary factors catalysing the growth of the global HIV drugs market is increase in the prevalence of HIV and its diagnosis. Apart from this, the market is also influenced by a rise in the number of government initiatives for spreading the awareness amongst people regarding causes, symptoms and treatments. Moreover, the introduction of generic drugs, which are cost-effective and chemically identical to branded drugs, act as another factor that is contributing towards the demand for HIV drugs.
IMARC Group provides an analysis of the key trends in each sub-segment of the global HIV drugs market, along with forecasts at the global and regional level from 2022-2027. Our report has categorized the market based on drug class and distribution channel.
Breakup by Drug Class:
Based on drug class, the market has been segmented into multi-class combination products, nucleoside reverse transcriptase inhibitors, non-nucleoside reverse transcriptase inhibitors, protease inhibitors, fusion inhibitors, entry inhibitors - CCR5 co-receptor antagonist and HIV integrase strand transfer inhibitors.
Breakup by Distribution Channel:
On the basis of distribution channel, the market is segregated as hospital pharmacies, retail pharmacies, online pharmacies and others. Hospital pharmacies currently account for the largest share.
Region-wise, the market has been segmented into Europe, Asia Pacific, North America, Middle East and Africa and Latin America. Amongst these, North America is the leading market accounting for the majority of the global market.
The competitive landscape of the market has also been examined with some of the key players being Boehringer Ingelheim International GmbH, Merck & Co., Inc., ViiV Healthcare, AbbVie, F. Hoffmann-La Roche Ltd., Teva Pharmaceutical Industries Ltd., Bristol-Myers Squibb Gilead Sciences, Inc., Johnson & Johnson, Cipla Limited, Daiichi Sankyo, Emcure, Hetero Drugs, and Mylan.
This report provides a deep insight into the global HIV drugs market covering all its essential aspects. This ranges from macro overview of the market to micro details of the industry performance, recent trends, key market drivers and challenges, SWOT analysis, Porter’s five forces analysis, value chain analysis, etc. This report is a must-read for entrepreneurs, investors, researchers, consultants, business strategists, and all those who have any kind of stake or are planning to foray into the HIV drugs market in any manner.
|Base Year of the Analysis||2021|
|Segment Coverage||Class, Distribution Channel, Region|
|Region Covered||Asia Pacific, Europe, North America, Latin America, Middle East and Africa|
|Companies Covered||Boehringer Ingelheim International GmbH, Merck & Co., Inc., ViiV Healthcare, AbbVie, F. Hoffmann-La Roche Ltd., Teva Pharmaceutical Industries Ltd., Bristol-Myers Squibb Gilead Sciences, Inc., Johnson & Johnson, Cipla Limited, Daiichi Sankyo, Emcure, Hetero Drugs, and Mylan|
|Customization Scope||10% Free Customization|
|Report Price and Purchase Option||Single User License: US$ 2499
Five User License: US$ 3499
Corporate License: US$ 4499
|Post-Sale Analyst Support||10-12 Weeks|
|Delivery Format||PDF and Excel through Email (We can also provide the editable version of the report in PPT/Word format on special request)|
The global HIV drugs market reached a value of US$ 29.2 Billion in 2021.
According to the estimates by IMARC Group, the global HIV drugs market is expected to exhibit a CAGR of 3.7% during 2022-2027.
The increasing prevalence of HIV and its diagnosis represents one of the key drivers for the global HIV drugs market.
The introduction of generic drugs that are cost-effective and chemically-identical to branded drugs represents one of the key trends in the global HIV drugs market.
Sudden outbreak of the COVID-19 pandemic had led to the implementation of stringent lockdown regulations and state of emergency across several nations resulting in disrupted supply chains for HIV drugs.
On the basis of the drug class, the market has been bifurcated into multi-class combination products, nucleoside reverse transcriptase inhibitors, non-nucleoside reverse transcriptase inhibitors, protease inhibitors, fusion inhibitors, entry inhibitors - CCR5 co-receptor antagonist, and HIV integrase strand transfer inhibitors. Amongst these, nucleoside reverse transcriptase inhibitors hold the majority of the total market share.
On the basis of the distribution channel, the market has been classified into hospital pharmacies, retail pharmacies, online pharmacies, and others. At present, hospital pharmacies exhibit a clear dominance in the market.
Region-wise, the market has been classified into North America, Europe, Asia Pacific, Middle East and Africa, and Latin America, where North America dominates the global market.
REACH OUT TO US
Call us on
( US: +1-631-791-1145 )
( UK: +44-753-713-2163 )
( India: +91 120 433 0800 )
Drop us an email at